SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

<p>JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/scynexis-presents-new-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-congress-on-trends-in-medical-mycology-timm/">SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>